Combination treatment of recombinant growth differentiation factor-9 and Cetrorelix improves gestational origin of the polycystic ovarian syndrome in female rats.
Sign Up to like & getrecommendations! Published in 2023 at "Life sciences"
DOI: 10.2139/ssrn.4355248
Abstract: AIMS Polycystic ovary syndrome (PCOS) is a hyper-androgenic endocrinopathy prevalent in premenopausal women with no cure available. The current study aimed to investigate the therapeutic effect of recombinant GDF-9 and Cetrorelix on the gestational origin… read more here.
Keywords: gestational origin; syndrome; combination treatment; treatment ... See more keywords